{
  "extraction_metadata": {
    "timestamp": "2025-10-01T10:55:56.038177",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "temperature": 0.3
  },
  "outcomes_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "Outcomes": "all-cause mortality, overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), disease control rate (DCR), time to symptomatic progression (TTSP), mRECIST response, complication incidence, pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), fatigue (EORTC QLQ-HCC18), diarrhoea, hand-foot-skin reaction, hypertension, skin rash, skin desquamation, hypody, post-treatment complications, liver failure, health status (EQ-5D visual analogue scale), global health status (EORTC QLQ-C30), function scales (EORTC QLQ-C30), function scales (EORTC QLQ-HCC18), disease recurrence, length of hospital stay, days of missed work",
      "ChunksUsed": 15,
      "ContextTokens": 2999
    },
    "CZ": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "CZ",
      "Outcomes": "",
      "ChunksUsed": 1,
      "ContextTokens": 202
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "Outcomes": "all-cause mortality, overall survival (OS), tumor response rate, adverse events, quality of life, liver function, tumor reduction, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), hand-foot-skin reaction, diarrhoea, hypertension, skin rash, desquamation, hypodynamia, pain (EORTC QLQ-HCC18), jaundice (EORTC QLQ-HCC18), fever (EORTC QLQ-HCC18), abdominal swelling (EORTC QLQ-HCC18), liver failure, post-treatment complications, health status (EQ-5D visual analogue scale), global health status (EORTC QLQ-C30), function scales (EORTC QLQ-C30), function scales (EORTC QLQ-HCC18), disease recurrence, length of hospital stay, days of missed work, complications",
      "ChunksUsed": 15,
      "ContextTokens": 3168
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), progression-free survival (stratified log-rank), time to progression (TTP), objective response rate (ORR), tumour response rate, complete response (CR), partial response (PR), time to response, duration of response, disease control rate (DCR; mRECIST), clinical benefit rate (CBR), plasma pharmacokinetics lenvatinib exposure parameters, adverse events (serious), adverse events (leading to discontinuation), adverse events (occurring in >10% of patients), treatment-emergent adverse events (TEAEs), diarrhoea, nutrition, pain, body image, role functioning, EORTC QLQ-C30, EORTC QLQ-HCC18, EQ-5D, European Quality of Life questionnaire, health-related quality of life (HRQoL), time to clinically meaningful deterioration (EORTC QLQ-C30), time to clinically meaningful deterioration (EORTC QLQ-HCC18), blood and tumour biomarkers correlated with clinical outcomes, cost-effectiveness analysis",
      "ChunksUsed": 15,
      "ContextTokens": 3078
    },
    "EN": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EN",
      "Outcomes": "overall survival, time to radiological disease progression, time to symptomatic disease progression (FHSI-8 questionnaire), diarrhoea, hand-foot skin reaction, adverse events (general), cost-effectiveness (incremental cost-effectiveness ratio, ICER), quality-adjusted life years (QALYs)",
      "ChunksUsed": 15,
      "ContextTokens": 2828
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "Outcomes": "overall survival (OS; time from randomisation to death from any cause), progression-free survival (PFS; time from randomisation to tumour progression defined by RECIST 1.1 or death from any cause), objective response rate (ORR; percentage of patients with partial or complete response; RECIST 1.1), objective response rate (ORR; percentage of patients with partial or complete response; mRECIST for liver disease), duration of response (DoR; time from partial or complete response to disease progression or exit), deterioration in patient quality of life (EORTC QLQ-C30), deterioration in patient quality of life (EORTC QLQ-HCC18), arterial hypertension, proteinuria, gastrointestinal disorders, bleeding, infections, liver disorders, hypothyroidism, infusion reactions, hyperthyroidism, hypertension, diabetes mellitus, adverse events (general), drug withdrawal due to adverse events, dose modification due to adverse events",
      "ChunksUsed": 15,
      "ContextTokens": 4373
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression, objective response rate (ORR), disease control rate, clinical benefit rate, quality of life (EQ5D-3L), EORTC QLQ-C30, EORTC QLQ-HCC18, adverse events (general), serious adverse events, grade 3 adverse reactions, treatment-related deaths, hepatotoxicity, hypertension, decreased appetite, weight loss, fatigue, hand-foot syndrome, proteinuria, dysphonia, alopecia, hepatic encephalopathy, hepatic insufficiency, arterial thromboembolic events, haemorrhagic events, hypothyroidism, renal adverse events, brain haemorrhage, sepsis, brain/gastrointestinal bleeding, intestinal failure, respiratory failure, cerebral vascular accident, cardiovascular arrest, myocardial infarction, sudden death, discontinuation of treatment due to adverse events",
      "ChunksUsed": 15,
      "ContextTokens": 3841
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "Outcomes": "overall survival, time to symptom progression, time to progression, disease control, partial response, minor response (reduction of tumour size by 25 to 50%), stable disease (for at least 16 weeks), fatigue, bleeding, abdominal pain, hypertension, diarrhoea, lymphoedema, hand feeding reactions, adverse reactions (general), cost-effectiveness analysis",
      "ChunksUsed": 15,
      "ContextTokens": 2530
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), complete response (CR), partial response (PR), stable disease (SD), disease control rate (DCR), EQ-5D (Euro QoL – 5 dimensions), EQ VAS (Euro QoL visual analogue scale), FACT-G (Functional Assessment of Cancer Therapy – General), number needed to harm (NNH), number needed to treat (NNT), hazard ratio (HR), mean difference (MD), relative risk (RR), risk difference (RD), hand-foot skin reaction, diarrhoea, rash, skin desquamation, fatigue, weight loss, hypertension, decreased appetite, hypocalcaemia, increased alanine aminotransferase (ALT) activity, alopecia, secondary cancer, dyspnoea, pleural effusion, cough, back pain, limb pain, infections, lymphopenia, anorexia, hypophosphataemia, haemorrhage, vomiting, constipation, dry skin, erythema, pruritus, arthralgia, pain, fever, decreased weight, increased amylase, increased lipase, folliculitis, leukopenia, neutropenia, anaemia, thrombocytopenia, hypothyroidism, hypokalaemia, hyponatraemia, hypoglycaemia, depression, peripheral sensory neuropathy, dysgeusia, tinnitus, congestive heart failure, myocardial ischaemia, myocardial infarction, flushing, rhinorrhoea, dysphonia, stomatitis, dyspepsia, dysphagia, gastro-oesophageal reflux disease, keratoacanthoma, squamous cell cancer of the skin, dermatitis exfoliative, acne, hyperkeratosis, myalgia, muscle spasms, renal failure, proteinuria, erectile dysfunction, asthenia, influenza-like illness, mucosal inflammation, transient increase in transaminases, adverse events (general), deaths",
      "ChunksUsed": 15,
      "ContextTokens": 3614
    },
    "PT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PT",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), quality of life, pharmacokinetic parameters, vital signs recording, laboratory haematological testing, laboratory biochemical testing, urinalysis, electrocardiography, adverse events (graded according to the National Cancer Institute), grade 3 adverse reactions, grade 4 adverse reactions, treatment-related mortality, dropout rate for toxicity, EORTC QLQ-C30, EORTC QLQ-HCC18",
      "ChunksUsed": 15,
      "ContextTokens": 2530
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "Outcomes": "overall survival (OS; time from randomization to death from any cause), progression-free survival (PFS), objective tumour response, time to tumour progression, adverse reactions leading to discontinuation of treatment, quality of life weights, health state utility values, cost per quality-adjusted life year (QALY), cost-benefit analysis",
      "ChunksUsed": 15,
      "ContextTokens": 2695
    }
  }
}